Lower Doses of CPX-351 as a Novel Approach for the Treatment of Older Patients With Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Acute myeloid leukaemia; Acute myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 10 Jul 2024 Planned End Date changed from 1 Jun 2026 to 1 Dec 2026.
- 10 Jul 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Dec 2024.
- 13 Nov 2023 Planned End Date changed from 1 Dec 2025 to 1 Jun 2026.